Table 2 Demographic data of study subjects used in tumour necrosis factor-α and lymphotoxin α1β2 stimulation experiments
From: Impaired lymph node stromal cell function during the earliest phases of rheumatoid arthritis
Healthy control subjects (n = 5) | Individuals with RA risk (n = 5) | Patients with early RAa (n = 5) | |
|---|---|---|---|
Passages | P4–P6 | P5–P8 | P6–P7 |
Female sex, n (%) | 5 (100) | 5 (100) | 4 (80) |
Median age, years (IQR) | 28 (26–40) | 51 (49–57) | 35 (28–58) |
IgM-RF-positive, n (%) | 0 (0) | 4 (80) | 3 (60) |
IgM-RF level, kU/L, median (IQR) | – | 3 (1–42) | 6 (3–288) |
ACPA-positive, n (%) | 0 (0) | 4 (80) | 4 (80) |
ACPA level, kAU/L, median (IQR) | – | 47 (16–343) | 54 (22–1563) |
IgM-RF and ACPA both positive, n (%) | 0 (0) | 0 (0) | 2 (40) |
DAS28, median (IQR) | – | – | 3.9 (3–7) |
CRP, mg/L, median (IQR) | 0.4 (0.3–2.7) | 3.2 (1.9–4.4) | 3 (0.9–100.4) |